Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives

Fan, Xinxiang; He, Weiyang; Huang, Jian

doi:10.21037/tau-23-124

Cited by 6 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En los protocolos contemporáneos de conservación de la vejiga, la terapia trimodal es la más usada, consiste en RTUV seguida de radioterapia y quimioterapia concurrente. En este contexto, la quimioterapia se administra concurrente como radiosensibilizador 5 . Entre los citostáticos usados en la concurrencia encontramos: cisplatino, paclitaxel, 5-fluorouracilo, mitomicina y gemcitabina 4 .…”

Section: Discussionunclassified

Nimotuzumab, emergente alternativa inmunoterapéutica en el carcinoma urotelial de vejiga. Reporte de caso

Carballo-Torres,

Caballero-Aguirrechu,

Vassallo-Labrada

et al. 2024

GAMO

View full text Add to dashboard Cite

Section: Discussionunclassified

Nimotuzumab, emergente alternativa inmunoterapéutica en el carcinoma urotelial de vejiga. Reporte de caso

Carballo-Torres,

Caballero-Aguirrechu,

Vassallo-Labrada

et al. 2024

GAMO

View full text Add to dashboard Cite

“…This could largely be due to concerns about metastasis and its being considered less effective in the more advanced stages of BCa. TMT consists of TURBT, chemotherapy, and radiotherapy combined, therefore removing the need for bladder removal [62].…”

Section: Bladder Sparing Alternativesmentioning

confidence: 99%

“…The selection criteria for TMT are reasonably restrictive, but it is the range of risk factors that suggest a poor prognosis following treatment that is also problematic when making the decision about who is an optimal candidate [62]. Patient selection factors include identifying those that can tolerate chemotherapy and radiation to the pelvic region, which comes with its own list of gastrointestinal side effects, as well as those that do not have a history of lower urinary tract conditions.…”

Section: Bladder Sparing Alternativesmentioning

confidence: 99%

Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement

Gill,

Perks

2024

IJMS

View full text Add to dashboard Cite

Bladder cancer is the tenth most common cancer and is a significant burden on health care services worldwide, as it is one of the most costly cancers to treat per patient. This expense is due to the extensive treatment and follow-ups that occur with costly and invasive procedures. Improvement in both treatment options and the quality of life these interventions offer has not progressed at the rates of other cancers, and new alternatives are desperately needed to ease the burden. A more modern approach needs to be taken, with urinary biomarkers being a positive step in making treatments more patient-friendly, but there is still a long way to go to make these widely available and of a comparable standard to the current treatment options. New targets to hit the major signalling pathways that are upregulated in bladder cancer, such as the PI3K/AkT/mTOR pathway, are urgently needed, with only one drug approved so far, Erdafitinib. Immune checkpoint inhibitors also hold promise, with both PD-1 and CDLA-4 antibody therapies approved for use. They effectively block ligand/receptor binding to block the immune checkpoint used by tumour cells. Other avenues must be explored, including drug repurposing and novel biomarkers, which have revolutionised this area in other cancers.

show abstract

“… 44 A number of other observational studies have compared oncological outcomes between RC and TMT, demonstrating 5‐year OS and CSS rates of 50% and 84% for RC, compared with 36% and 74% for TMT. 45 The emphasis through all bladder sparing studies is the importance of patient selection ensuring patients are without invasion beyond the muscularis propria, hydronephrosis, carcinoma in situ or multifocal disease. 46 Nevertheless, both TMT and the trials discussed above (BC2001 and BCON) are associated with 10‐year OS of only 30%, with increasing salvage cystectomy rates.…”

Section: Bladder Cancermentioning

confidence: 99%

Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies

Skalina,

Małachowska,

Sindhu

et al. 2023

BJUI Compass

View full text Add to dashboard Cite

Particle therapy and radiopharmaceuticals are emerging fields in the treatment of genitourinary cancers. With these novel techniques and the ever‐growing immunotherapy options, the combinations of these therapies have the potential to improve current cancer cure rates. However, the most effective sequence and combination of these therapies is unknown and is a question that is actively being explored in multiple ongoing clinical trials. Here, we review the immunological effects of particle therapy and the available radiopharmaceuticals and discuss how best to combine these therapies.

show abstract

Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives

Cited by 6 publications

References 48 publications

Nimotuzumab, emergente alternativa inmunoterapéutica en el carcinoma urotelial de vejiga. Reporte de caso

Nimotuzumab, emergente alternativa inmunoterapéutica en el carcinoma urotelial de vejiga. Reporte de caso

Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement

Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies

Contact Info

Product

Resources

About